Medincell (France) Performance
| MEDCL Stock | EUR 16.38 0.20 1.24% |
The company secures a Beta (Market Risk) of -0.21, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Medincell are expected to decrease at a much lower rate. During the bear market, Medincell is likely to outperform the market. At this point, Medincell SA has a negative expected return of -0.1%. Please make sure to verify Medincell's potential upside, and the relationship between the jensen alpha and daily balance of power , to decide if Medincell SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medincell SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
| Begin Period Cash Flow | 47.1 M | |
| Total Cashflows From Investing Activities | -316 K |
Medincell |
Medincell Relative Risk vs. Return Landscape
If you would invest 1,794 in Medincell SA on November 8, 2024 and sell it today you would lose (156.00) from holding Medincell SA or give up 8.7% of portfolio value over 90 days. Medincell SA is generating negative expected returns and assumes 2.9585% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than Medincell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medincell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medincell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medincell SA, and traders can use it to determine the average amount a Medincell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0349
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MEDCL |
Estimated Market Risk
| 2.96 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medincell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medincell by adding Medincell to a well-diversified portfolio.
Medincell Fundamentals Growth
Medincell Stock prices reflect investors' perceptions of the future prospects and financial health of Medincell, and Medincell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medincell Stock performance.
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 180.29 M | |||
| Shares Outstanding | 25.22 M | |||
| Price To Book | 27.59 X | |||
| Price To Sales | 20.97 X | |||
| Revenue | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Cash And Equivalents | 5 M | |||
| Cash Per Share | 1.24 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.61 % | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (1.12) X | |||
| Total Asset | 44.3 M | |||
About Medincell Performance
Assessing Medincell's fundamental ratios provides investors with valuable insights into Medincell's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Medincell is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. MEDINCELL is traded on Paris Stock Exchange in France.Things to note about Medincell SA performance evaluation
Checking the ongoing alerts about Medincell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medincell SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medincell SA generated a negative expected return over the last 90 days | |
| The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M. | |
| Medincell SA has accumulated about 5 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24. | |
| Roughly 47.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Medincell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medincell's stock is overvalued or undervalued compared to its peers.
- Examining Medincell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medincell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medincell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medincell's stock. These opinions can provide insight into Medincell's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medincell Stock Analysis
When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.